CRISPR Therapeutics (NASDAQ: CRSP) holds commercial rights to the first CRISPR-based gene editing therapy approved by the FDA. This milestone validates the entire gene editing sector.
The Science
CRISPR-Cas9 acts as molecular scissors that can cut DNA at precise locations, allowing scientists to disable disease-causing genes or insert corrective sequences. The technology can potentially cure genetic diseases at the DNA level rather than treating symptoms. The research behind it won the 2020 Nobel Prize in Chemistry, which is more than background color: it is why capital keeps flowing into the field even through bear markets.
What Would Change the Story
The bull path runs through patient starts, not headlines. Casgevy requires cell collection, manufacturing, and conditioning chemotherapy before infusion, so the ramp is measured in dozens of patients per quarter, not thousands, and hospital committees move slowly on 2.2 million dollar therapies. Watch the patient initiation counts Vertex discloses each quarter. The second lever is pipeline: proof-of-concept data in the cardiovascular programs would move the multiple from one-product territory toward platform territory. The bear path is administrative: a safety flag, a payer revolt, or a competing therapy that ends the sickle cell monopoly.
Casgevy: The First Approved Therapy
In December 2023, FDA approved Casgevy for sickle cell disease - the first CRISPR-based therapy to receive clearance. The UK regulator cleared it weeks earlier, making it the first anywhere. The treatment modifies a patient's own stem cells to produce fetal hemoglobin. Price: 2.2 million dollars per patient. Market: approximately 25,000 eligible patients in the US and EU.
Vertex Holds the Commercial Reins
Casgevy economics flow through a joint venture with Vertex Pharmaceuticals, which runs commercialization and holds roughly 60 percent of profit against CRSP's 40. Revenue detail therefore shows up in Vertex reports, not CRSP releases, and Vertex commentary moves CRSP as much as its own news. Treat the two as correlated positions: holding both doubles exposure to the same approval story.
The Competing Editors
Three rivals share the gene editing label with very different profiles. Beam Therapeutics works on base editing, a gentler technique that avoids double-strand DNA breaks. Intellia runs in vivo programs that edit genes inside the body rather than in extracted cells. Editas, once the sector name, has retrenched after clinical setbacks. On sector selloffs all four trade together, which is precisely when relative strength separates the survivors from the stories.
Pipeline
Beyond Casgevy, CRSP has programs in cardiovascular disease and immuno-oncology in early-stage trials. Proof-of-concept readouts in those programs land years before any approval, and each one reprices the stock long before revenue could.
Stock Performance
CRSP trades around 57 dollars at a market capitalization of 4.7 billion. The 52-week range is 39.50 to 72.22. Cash position of approximately 1.8 billion provides runway through 2027, which removes the dilution question for a few years, a rare luxury in biotech. Note the sector beta too: CRSP rarely moves alone, and weak days in the biotech indices drag it regardless of company news.
Trading CRSP on Ngernswap
Biotech stocks trade on binary events - clinical trial data, FDA decisions, competitor readouts. On Ngernswap, use bracket orders with wider-than-normal stops around announcements, because implied moves through catalysts run two to three times a normal session. Halve position size going into advisory committee votes, and let the post-data gap fill before adding. Support at 50 (200-day average). Resistance at 65 and 72. A move above 72 signals new momentum.
The science is real - Nobel Prize real. The commercial timeline is uncertain. Trade the volatility, invest in the thesis. In practice on Ngernswap, that means a small core held across readouts plus event trades sized for the gap risk, with the bracket attached before the catalyst, never after.